11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Intuniv XR

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Gaunfacin

Gaunfacin

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Nøvik TS, Hervas A, Ralston SJ, Dalsgaard S, Rodrigues Pereira R, Lorenzo MJ et al. Influence of gender on attention-deficit/hyperactivity disorder in Europe--ADORE. Eur Child Adolesc Psychiatry. 2006;15 Suppl 1:I15-24.

  2. Ramtekkar UP, Reiersen AM, Todorov AA, Todd RD. Sex and age differences in attention-deficit/hyperactivity disorder symptoms and diagnoses: implications for DSM-V and ICD-11. J Am Acad Child Adolesc Psychiatry. 2010;49(3):217-28e1-3.

  3. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9(3):490-9.

  4. Gaub M, Carlson CL. Gender differences in ADHD: a meta-analysis and critical review. J Am Acad Child Adolesc Psychiatry. 1997;36(8):1036-45.

  5. Biederman J, Faraone SV, Monuteaux MC, Bober M, Cadogen E. Gender effects on attention-deficit/hyperactivity disorder in adults, revisited. Biol Psychiatry. 2004;55(7):692-700.

  6. Mowlem FD, Rosenqvist MA, Martin J, Lichtenstein P, Asherson P, Larsson H. Sex differences in predicting ADHD clinical diagnosis and pharmacological treatment. Eur Child Adolesc Psychiatry. 2019;28(4):481-489.

  7. Socialstyrelsen. Stöd till barn, ungdomar och vuxna med adhd. Socialstyrelsen.

  8. Mowlem F, Agnew-Blais J, Taylor E, Asherson P. Do different factors influence whether girls versus boys meet ADHD diagnostic criteria? Sex differences among children with high ADHD symptoms. Psychiatry Res. 2019;272:765-773.

  9. Kok FM, Groen Y, Fuermaier ABM, Tucha O. The female side of pharmacotherapy for ADHD-A systematic literature review. PLoS One. 2020;15(9):e0239257.

  10. Intuniv (guanfacine). EPAR - Product information. European Medicines Agency (EMA) [updated 2021-11-25, cited 2022-02-02]

  11. Clinical Pharmacology and Biopharmaceutics Review - INTUNIV (guanfacine). Drugs@FDA [www]. Food and Drug Administration (FDA). [updated 2009-02-09, cited 2022-02-02].

  12. Boellner SW, Pennick M, Fiske K, Lyne A, Shojaei A. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy. 2007;27(9):1253-62.

  13. Knebel W, Corcoran M, Ermer J, Gastonguay MR. Population Pharmacokinetic Modeling of Guanfacine in Pediatric Patients. Clin Pharmacokinet. 2015;54(8):875-83.

  14. Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol. 2014;24(12):1861-72.

  15. Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R et al. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(11):916-25e2.

  16. Newcorn JH, Harpin V, Huss M, Lyne A, Sikirica V, Johnson M et al. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study. J Child Psychol Psychiatry. 2016;57(6):717-28.

  17. Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73-84.

  18. Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155-65.

  19. Newcorn JH, Stein MA, Childress AC, Youcha S, White C, Enright G et al. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J Am Acad Child Adolesc Psychiatry. 2013;52(9):921-30.

  20. Stein MA, Sikirica V, Weiss MD, Robertson B, Lyne A, Newcorn JH. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial. CNS Drugs. 2015;29(11):953-62.

  21. Naya N, Sakai C, Okutsu D, Kiguchi R, Fujiwara M, Tsuji T et al. Efficacy and safety of guanfacine extended-release in Japanese adults with attention-deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study. Neuropsychopharmacol Rep. 2021;41(1):26-39.

  22. Knebel W, Ermer J, Purkayastha J, Martin P, Gastonguay MR. Population pharmacokinetic/pharmacodynamic modeling of guanfacine effects on QTc and heart rate in pediatric patients. AAPS J. 2014;16(6):1237-46.

  23. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2020 [cited 2021-03-10.]

  1. Nøvik TS, Hervas A, Ralston SJ, Dalsgaard S, Rodrigues Pereira R, Lorenzo MJ et al. Influence of gender on attention-deficit/hyperactivity disorder in Europe--ADORE. Eur Child Adolesc Psychiatry. 2006;15 Suppl 1:I15-24.
  2. Ramtekkar UP, Reiersen AM, Todorov AA, Todd RD. Sex and age differences in attention-deficit/hyperactivity disorder symptoms and diagnoses: implications for DSM-V and ICD-11. J Am Acad Child Adolesc Psychiatry. 2010;49(3):217-28e1-3.
  3. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9(3):490-9.
  4. Gaub M, Carlson CL. Gender differences in ADHD: a meta-analysis and critical review. J Am Acad Child Adolesc Psychiatry. 1997;36(8):1036-45.
  5. Biederman J, Faraone SV, Monuteaux MC, Bober M, Cadogen E. Gender effects on attention-deficit/hyperactivity disorder in adults, revisited. Biol Psychiatry. 2004;55(7):692-700.
  6. Mowlem FD, Rosenqvist MA, Martin J, Lichtenstein P, Asherson P, Larsson H. Sex differences in predicting ADHD clinical diagnosis and pharmacological treatment. Eur Child Adolesc Psychiatry. 2019;28(4):481-489.
  7. Socialstyrelsen. Stöd till barn, ungdomar och vuxna med adhd. Socialstyrelsen.
  8. Mowlem F, Agnew-Blais J, Taylor E, Asherson P. Do different factors influence whether girls versus boys meet ADHD diagnostic criteria? Sex differences among children with high ADHD symptoms. Psychiatry Res. 2019;272:765-773.
  9. Kok FM, Groen Y, Fuermaier ABM, Tucha O. The female side of pharmacotherapy for ADHD-A systematic literature review. PLoS One. 2020;15(9):e0239257.
  10. Intuniv (guanfacine). EPAR - Product information. European Medicines Agency (EMA) [updated 2021-11-25, cited 2022-02-02]
  11. Clinical Pharmacology and Biopharmaceutics Review - INTUNIV (guanfacine). Drugs@FDA [www]. Food and Drug Administration (FDA). [updated 2009-02-09, cited 2022-02-02].
  12. Boellner SW, Pennick M, Fiske K, Lyne A, Shojaei A. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy. 2007;27(9):1253-62.
  13. Knebel W, Corcoran M, Ermer J, Gastonguay MR. Population Pharmacokinetic Modeling of Guanfacine in Pediatric Patients. Clin Pharmacokinet. 2015;54(8):875-83.
  14. Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol. 2014;24(12):1861-72.
  15. Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R et al. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(11):916-25e2.
  16. Newcorn JH, Harpin V, Huss M, Lyne A, Sikirica V, Johnson M et al. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study. J Child Psychol Psychiatry. 2016;57(6):717-28.
  17. Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73-84.
  18. Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155-65.
  19. Newcorn JH, Stein MA, Childress AC, Youcha S, White C, Enright G et al. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J Am Acad Child Adolesc Psychiatry. 2013;52(9):921-30.
  20. Stein MA, Sikirica V, Weiss MD, Robertson B, Lyne A, Newcorn JH. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial. CNS Drugs. 2015;29(11):953-62.
  21. Naya N, Sakai C, Okutsu D, Kiguchi R, Fujiwara M, Tsuji T et al. Efficacy and safety of guanfacine extended-release in Japanese adults with attention-deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study. Neuropsychopharmacol Rep. 2021;41(1):26-39.
  22. Knebel W, Ermer J, Purkayastha J, Martin P, Gastonguay MR. Population pharmacokinetic/pharmacodynamic modeling of guanfacine effects on QTc and heart rate in pediatric patients. AAPS J. 2014;16(6):1237-46.
  23. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2020 [cited 2021-03-10.]